バイエルさんのインスタグラム写真 - (バイエルInstagram)「Curing and preventing cancer is one of the main focus areas of @leapsbybayer. Thus, we’re excited to support the development of next-generation cancer therapies that promise to address previously incurable cancers. Triumvira Immunologics Inc. (“Triumvira”), a privately-held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, successfully completed a USD 55 million Series A financing round. The financing was co-led by Leaps by Bayer, the impact investment unit of Bayer, and Northpond Ventures.」8月27日 20時30分